Topas Therapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Topas Therapeutics GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11071
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Topas Therapeutics GmbH (Topas Therapeutics) is a biotechnological company that designs and develops nanoparticle products loaded with antigenic peptides. The company’s pre-clinical pipeline categories are used in the treatment of allergies, immune mediated diseases, autoimmune diseases, and anti-drug-antibodies (ADA) induced conditions. It incorporates its unique approach to induce immune tolerance in blood borne antigens using liver sinusoidal endothelial cells (LSECs) to produce tolerogenic regulatory T cells (Tregs). Topas Therapeutics employs T cell-specific peptide antigen-loaded nanoparticles in proof of concept studies to treat immune-mediated diseases. The company’s therapeutic focus spans on the areas of neurology and immunology. Topas Therapeutics is headquartered in Hamburg, Germany.

Topas Therapeutics GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Topas Therapeutics Raises Additional USD5 Million in Series A Financing 10
Topas Therapeutics Raises USD15.8 Million in Series A Financing 11
Partnerships 13
Topas Therapeutics Enters into Agreement with Boehringer Ingelheim 13
Topas Therapeutics Enters into Research Agreement with Eli Lilly 14
Equity Offering 15
Evotec Spin Out from Topas Therapeutics 15
Topas Therapeutics GmbH – Key Competitors 16
Topas Therapeutics GmbH – Key Employees 17
Topas Therapeutics GmbH – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Oct 26, 2017: Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer 19
Apr 04, 2017: Paul Sekhri joins Topas Therapeutics as Chairman of the Board 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Topas Therapeutics GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Topas Therapeutics Raises Additional USD5 Million in Series A Financing 10
Topas Therapeutics Raises USD15.8 Million in Series A Financing 11
Topas Therapeutics Enters into Agreement with Boehringer Ingelheim 13
Topas Therapeutics Enters into Research Agreement with Eli Lilly 14
Evotec Spin Out from Topas Therapeutics 15
Topas Therapeutics GmbH, Key Competitors 16
Topas Therapeutics GmbH, Key Employees 17

List of Figures
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Topas Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Topas Therapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • 1414 Degrees Ltd (14D):企業の財務・戦略的SWOT分析
    1414 Degrees Ltd (14D) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • HLS Therapeutics Inc (HLS):製薬・医療:M&Aディール及び事業提携情報
    Summary HLS Therapeutics Inc (HLS Therapeutics) is a pharmaceutical company that offers central nervous system and cardiovascular therapeutic products. The company's product includes clozaril, absorica, vascepa and trinomial. Its clozapine is a pharmaceutical product used in the treatment of schizop …
  • Wacker Chemie AG (WCH):企業の財務・戦略的SWOT分析
    Wacker Chemie AG (WCH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • DURECT Corp (DRRX):企業の財務・戦略的SWOT分析
    DURECT Corp (DRRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Mylan NV (MYL)-医療機器分野:企業M&A・提携分析
    Summary Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, ca …
  • Biocept Inc (BIOC):医療機器:M&Aディール及び事業提携情報
    Summary Biocept Inc (Biocept) is a molecular diagnostics company. The company develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. It offers assays for solid tumor indications, such as breast cancer, non-small cell l …
  • Lumberg Connect GmbH:企業の戦略的SWOT分析
    Lumberg Connect GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • IO Biotech ApS:製薬・医療:M&Aディール及び事業提携情報
    Summary IO Biotech ApS (IO Biotech) is a clinical stage biotechnology company, which develops disruptive immune modulating anti-cancer medicines. The company developed a pipeline of first-in-class anti-cancer drugs harnessing a unique technology platform, T-Win. IO Biotech's immuno-oncology therapie …
  • HedgePath Pharmaceuticals Inc (HPPI):製薬・医療:M&Aディール及び事業提携情報
    Summary Hedgepath Pharmaceuticals Inc (Hedgepath), a subsidiary of Mayne Pharma Group Ltd, is a clinical stage biopharmaceutical company that discovers, develops and commercializes novel therapeutics for the treatment of skin, prostrate, and lung cancers. The company is investigating an oral formula …
  • Immucor, Inc.:企業の戦略的SWOT分析
    Immucor, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Conair Corporation
    Conair Corporation - Strategy, SWOT and Corporate Finance Report Summary Conair Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mirvac Group:企業の戦略・SWOT・財務情報
    Mirvac Group - Strategy, SWOT and Corporate Finance Report Summary Mirvac Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Pets at Home Group Plc (PETS):企業の財務・戦略的SWOT分析
    Pets at Home Group Plc (PETS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Weizmann Institute of Science:製薬・医療:M&Aディール及び事業提携情報
    Summary Weizmann Institute of Science (WIS) is a research institute that offers research activities in the field of natural and exact sciences. The institute provides programs that include graduate programs, post graduate programs, scientific research, academic affairs, science education, research a …
  • Pivotal Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pivotal Therapeutics Inc (Pivotal Therapeutics) is a pharmaceutical company that develops and markets Omega-3 based therapies and therapeutic products for cardiovascular disorders. The company offers products such as VASCAZEN, a medical food formulated for the dietary management of an Omega- …
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196)-医療機器分野:企業M&A・提携分析
    Summary Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism …
  • Poyry PLC:企業のM&A・事業提携・投資動向
    Poyry PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Poyry PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Dominion Energy Inc.:企業の戦略・SWOT・財務分析
    Dominion Energy Inc. - Strategy, SWOT and Corporate Finance Report Summary Dominion Energy Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Haisco Pharmaceutical Group Co Ltd (002653)-医療機器分野:企業M&A・提携分析
    Summary Haisco Pharmaceutical Group Co Ltd (Haisco Pharma), formerly Xizang Haisco Pharmaceutical Group Co Ltd is a developer and marketer of chemical drug preparations and bulk drugs. The company's product portfolio comprises injection for trace elements, compound vitamin, invert sugar, fat soluble …
  • Roche Diagnostics International Ltd-医療機器分野:企業M&A・提携分析
    Summary Roche Diagnostics International Ltd (Roche Diagnostics) offers novel diagnostic tests and systems for the early identification, targeted screening, assessment and monitoring of diseases. Its major products include point-of-care testing devices; analyzers, blood glucose meters; laboratory inf …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆